ID
45568
Descrição
Principal Investigator: Elaine Mardis, PhD, The Genome Institute, Washington University School of Medicine, St. Louis, MO, USA MeSH: Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000661 This study aims to elucidate the genetic determinants of susceptibility to aggressive prostate carcinoma. To this end, germ line whole exome sequence has been generated from patients with aggressive prostate cancer. Whole genome sequence for a representative subset of tumors from patients whose cancer was resistant to primary therapy is included as well. This deep genomic interrogation will allow the identification of rare, functionally disruptive variants that may play a role in disease progession and response to treatment.
Link
Palavras-chave
Versões (1)
- 23/01/2023 23/01/2023 - Dr. Christian Niklas
Titular dos direitos
Elaine Mardis, PhD, The Genome Institute, Washington University School of Medicine, St. Louis, MO, USA
Transferido a
23 de janeiro de 2023
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
dbGaP phs000661 Germline Sequencing for Aggressive Prostate Carcinoma
Subject ID, consent group, and affection status of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
- StudyEvent: SEV1
- Subject ID, consent group, and affection status of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
- Subject ID, sample ID, and sample use variable of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
- Subject ID and race of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
- Sample ID, body site from which the tissue sample originated, tumor status of sample, and age of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
Similar models
Subject ID, consent group, and affection status of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
- StudyEvent: SEV1
- Subject ID, consent group, and affection status of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
- Subject ID, sample ID, and sample use variable of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
- Subject ID and race of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
- Sample ID, body site from which the tissue sample originated, tumor status of sample, and age of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
C4684638 (UMLS CUI [1,2])
C0441833 (UMLS CUI [1,2])